Orphan Drugs Market 2015-2019

2015-11-11
Price :
Published : Nov-2015
No. of Pages : 108

An orphan drug is used to treat rare diseases or disorders. According to WHO, orphan or rare diseases are the pathological conditions that affect 0.65-1 out of 10,000 population worldwide. There are around 6,000 orphan diseases, of which 80% are genetic. Orphan drugs are developed by the pharmaceutical industry to serve the public health need. These are designated as “Orphan Designations” by the regulatory agencies to accelerate the approval process.

The analysts forecast global orphan drugs market to grow at a CAGR of 10.05% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the global orphan drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales orphan drugs.

The report, Global Orphan Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and Europe; it also covers the landscape of the global orphan drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • Europe

Key vendors

  • Bristol-Mayer Squibb
  • Celgene
  • F. Hoffmann La Roche
  • Novartis
  • Pfizer

Other prominent vendors

  • AbbVie
  • Actelion Pharmaceuticals
  • Alexion Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Baxter International
  • Biogen Idec
  • Celldex Therapeutics
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Intercept Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novo Nordisk
  • Onyx Pharmaceuticals
  • Sanofi
  • Shire
  • Synageva BioPharma
  • Takeda
  • Vertex Pharmaceuticals
  • XOMA

Market driver

  • Shorter development timelines
  • For a full, detailed list, view our report

Market challenge

  • High cost of drug development
  • For a full, detailed list, view our report

Market trend

  • Increased focus on biological drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

ForeSights: Salt Therapy – An old-fashioned, non-invasive treatment enjoying a renaissance as a new health and wellness solution

ForeSights: Salt Therapy - An old-fashioned, non-invasive treatment enjoying a renaissance as a new health and wellness solution Summary Salt therapy is a non-invasive treatment that uses aerated salt or a salt bath to deliver health and wellness benefits. It comes in two forms: dry salt therapy (halotherapy) and wet salt therapy (flotation therapy). Both forms of salt therapy are claimed to promote relaxation and rejuvenation. Salt therapy is an old-fashioned, drug-free treatment leveraging the claimed natural antibacterial and anti-inflammatory properties of salt that capitalizes on growing interest in complementary and alternative medicine. Scope - Dry salt therapy (halotherapy) takes mineral-rich salt and grinds it into a fine powder that is dispensed into the air to cre......
$495

EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2026 Summary Osteoarthritis (OA) is a gradually progressive joint disease that is typically seen in middle-aged to elderly people. According to the American College of Rheumatology (ACR), OA is the most common cause of disability in the elderly. The most commonly affected joints are the knee, hip, hand, and spine. It is characterized by breakdown of the cartilage, bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining. To forecast the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA in the 7MM, GlobalData epidemiologists selected nationally representative,......
$3995

Heart Transplant Rejection Global Clinical Trials Review, H2, 2017

Heart Transplant Rejection Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Heart Transplant Rejection Global Clinical Trials Review, H2, 2017" provides an overview of Heart Transplant Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Heart Transplant Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary dat......
$2500

Heart Valve Disease Global Clinical Trials Review, H2, 2017

Heart Valve Disease Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Heart Valve Disease Global Clinical Trials Review, H2, 2017" provides an overview of Heart Valve Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Heart Valve Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500

Helicobacter pylori Infections Global Clinical Trials Review, H2, 2017

Helicobacter pylori Infections Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Helicobacter pylori Infections Global Clinical Trials Review, H2, 2017" provides an overview of Helicobacter pylori Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Helicobacter pylori Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's......
$2500

Helminthiasis Global Clinical Trials Review, H2, 2017

Helminthiasis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Helminthiasis Global Clinical Trials Review, H2, 2017" provides an overview of Helminthiasis clinical trials scenario. This report provides top line data relating to the clinical trials on Helminthiasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500

Helminthic Infestations Global Clinical Trials Review, H2, 2017

Helminthic Infestations Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Helminthic Infestations Global Clinical Trials Review, H2, 2017" provides an overview of Helminthic Infestations clinical trials scenario. This report provides top line data relating to the clinical trials on Helminthic Infestations. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Hemangiomas Global Clinical Trials Review, H2, 2017

Hemangiomas Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemangiomas Global Clinical Trials Review, H2, 2017" provides an overview of Hemangiomas clinical trials scenario. This report provides top line data relating to the clinical trials on Hemangiomas. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Hematological Tumor Global Clinical Trials Review, H2, 2017

Hematological Tumor Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hematological Tumor Global Clinical Trials Review, H2, 2017" provides an overview of Hematological Tumor clinical trials scenario. This report provides top line data relating to the clinical trials on Hematological Tumor. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500

Hematoma Global Clinical Trials Review, H2, 2017

Hematoma Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hematoma Global Clinical Trials Review, H2, 2017" provides an overview of Hematoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hematoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500